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HIV gp120: double lock strategy foils host defences
Quentin J Sattentau
The recent determination of the structure of a complex
formed between the HIV-1 glycoprotein gp120, CD4 and an
antibody fragment has revealed new mechanisms for viral
evasion of the immune response and shed light on how
the virus enters target cells. The results of this work,
together with related biochemical studies, may assist in
the future design of therapeutic strategies against HIV-1
infection.
Address:  The Centre d’Immunologie de Marseille-Luminy, 163 Avenue
de Luminy, Case 906, 13288 Marseille Cedex 9, France.
E-mail:  sattenta@ciml.univ-mrs.fr
Structure 15 August 1998, 6:945–949
http://biomednet.com/elecref/0969212600600945
© Current Biology Publications ISSN 0969-2126
The function of the HIV envelope glycoproteins
As with all obligate intracellular parasites, the human
immunodeficiency virus type 1 (HIV-1) requires a portal of
entry into its target cells. To achieve this, the virus has
evolved a cell-surface attachment glycoprotein, gp120, and
a membrane spanning fusion glycoprotein, gp41; these
two proteins have functional homology with the HA1 and
HA2 glycoproteins, respectively, of influenza. The two
HIV-1 glycoproteins (termed Env which corresponds to the
product of the viral env gene), start life as a precursor
polypeptide, gp160. A cellular enzyme, furin or a close rela-
tive, cleaves gp160 into the activated, functional forms that
assemble into a trimer of gp120–gp41 heterodimers and are
transported to the plasma membrane. The cytoplasmic tail
of gp41 is targeted by immature viral cores that subse-
quently bud through the membrane, acquiring in this way
an envelope and forming mature infectious particles. 
To initiate a new infection, nascent particles need to
encounter a potential target cell that expresses the appro-
priate receptor structures. In the case of HIV, these are
the CD4 molecule, found principally on T lymphocytes,
macrophages and dendritic cells, and members of the
chemokine receptor family (termed ‘HIV coreceptors’ in
this context; reviewed in [1]). Two coreceptors, CXCR4
and CCR5, stand out as being of primary importance in
HIV infection; CCR5 is critical for virus transmission,
whereas CXCR4 is utilized by viruses that are implicated in
later stages of infection [2]. The primary HIV attachment
takes place via an association between gp120 and CD4.
The affinity of CD4 for monomeric gp120, either dissoci-
ated from virions or the recombinant form of the protein, is
high — between 1 and 10 nM. This does not, however,
necessarily reflect the affinity of functional oligomeric gp120
for CD4, which may be several orders of magnitude lower
[3,4]. The gp120 oligomer may therefore ‘store’ the energy
required for monomers of gp120 to undergo conforma-
tional changes that are integral to activation of the fusion
process. Unlike influenza, therefore, in which HA2-medi-
ated fusion is triggered by a reduction in endosomal pH,
HIV fusion is activated by receptor binding. On the basis
of antibody-binding studies, CD4-complexed gp120 has
been shown to have a modified conformation. Two promi-
nent conformational changes are induced on CD4 binding:
an increased exposure of a variable region of gp120 (the
V3 loop) [5] and the exposure of a surface recognized by
the 17b antibody [6]. Together, these two regions form
the coreceptor-binding site (CRbs) [7]. These observa-
tions have led to a proposed sequence of events for HIV-1
cell entry. It is thought that gp120 binds to CD4 inducing
conformational changes that lead to the formation of the
CRbs [8,9]. Once this site is exposed, the coreceptor is
able to bind and in doing so activates gp41-mediated
membrane fusion (reviewed in [10]; see Figure 1). The
precise details of HIV cell-membrane fusion have not yet
been elucidated, but we are beginning to understand how
gp41 might be activated. The two published structures of
the isolated gp41 core are considered to be in the activated
coiled-coil form, analogous to the low-pH form of HA2
[11,12]. It is possible that gp120 chaperones the energeti-
cally unstable preactivated form of gp41, and subsequent
receptor-induced modification of the gp120 oligomer is
sufficient to trigger gp41 activation.
The structure of the gp120–CD4–Fab complex
A comparison of the amino acid sequences of gp120 from
different viral origins identified five variable regions (V1–V5)
interspersed with five conserved regions. The variable
regions form loops on the surface of the protein, whereas
the conserved regions form a central core. The crystal
structure of a complex formed between the gp120 core,
CD4 and a neutralizing antibody fragment (Fab) has been
recently reported [13]. In order to obtain crystals that dif-
fracted to sufficient resolution, it was necessary to make
several modifications to the gp120 polypeptide. It had pre-
viously been established that V1, V2 and V3 are conforma-
tionally unstable, and that these loops and the N and C
termini are unnecessary for CD4 binding [14,15]. A trun-
cated, recombinant version of gp120 was therefore pro-
duced, in which these regions had been excized (Figure 2).
In addition, the majority (>90%) of the extensive glycosy-
lation was removed enzymatically [13]. Finally, the gp120
conformation was ‘locked’ by coupling it with the first two
domains of CD4 and an Fab fragment of an antibody now
known to interact with a portion of the CRbs [7]. Crystals
of this complex diffracted to 2.5 Å, yielding a rich source
of information concerning not only gp120 itself, but also
its interactions with both receptor and coreceptor [13].
The structure is entirely novel, containing only subtle
homologies with existing structures; the principal features
are summarized below.
The glycoprotein gp120 forms a globular structure, con-
sisting of 25 β strands, five α helices and ten loops. The
structure folds to form an ‘inner’ domain (containing the
N and C termini, which in intact Env would associate with
gp41), an ‘outer’ domain, and a minidomain (termed the
‘bridging sheet’) that links the inner and outer domains
(Figure 3). All three domains are important for CD4 and
coreceptor binding. The structure contains some variable
regions that include the previously determined V5 as well
as the LD and LE surface loops. Glycosylation is found
over much of the surface of the protein, and particularly
on the the outer domain.
The CD4-binding surface (CD4bs) comprises an area of
~800 Å2 and is located at the bottom of a depression
formed at the interface of the three domains (Figure 4a).
Part of this surface is relatively acidic, complementing a
basic patch on CD4. Within this surface are two major cav-
ities: one hydrophobic cavity (~150 Å3), and one water-
filled hydrophilic cavity (~280 Å3). Residues within the
hydrophobic cavity are highly conserved between gp120
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Figure 1
A model for HIV–receptor interactions leading to the fusion of the virus
and cell membrane. (a) A trimer of gp41–gp120 heterodimers (brown)
on the virus encounters CD4 (blue) on the surface of a target cell. The
CD4-binding site (CD4bs) becomes exposed subsequent to
displacement of the V1 and V2 variable loops (purple) in a transiently
expressed conformation, and domain 1 of a CD4 molecule attaches to
gp120. (b) CD4–gp120 binding induces conformational changes in
gp120, and forms the coreceptor-binding site (CRbs) by displacing
the V3 loop (yellow); gp120 attaches to the coreceptor (CR) via a
combination of the V3 loop and the conserved binding surface (shown
in magenta), bringing the virus and cell membranes into close
proximity. (c) Further conformational changes result in gp41 activation
that leads to insertion of the fusion peptide into the target-cell
membrane, and the formation of a coiled coil that snaps the virus and
cell membranes into close apposition. Membrane fusion follows by a
poorly defined mechanism.
Figure 2
The truncations introduced into gp120. Wild-
type gp120 (top) is shown with amino acid
sequence numbering and representation of
the five variable (V) and conserved (C)
segments. The truncated version (bottom)
shows the deletions introduced into the cDNA
coding for the protein used for crystallization.
The numbers represent the number of
residues deleted from the polypeptide; the V1,
V2 and V3 loops were substituted by Ala-Gly-
Ala insertions. S represents the signal
peptide.
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molecules of different origins, and the cavity is plugged by
the Phe43 residue of CD4 that is critical for the CD4–
gp120 interaction. In contrast, the hydrophilic cavity is
unoccupied by CD4 and is lined with variable residues.
These two cavities probably reflect the stabilization of an
energetically unfavourable gp120 conformation by CD4.
The conserved portion of the CRbs is overlapped in the
structure by the gp120 interface with the 17b Fab frag-
ment. The interface between gp120 and the Fab fragment
buries ~450 Å2 surface area composed mainly of basic and
hydrophobic residues that are highly conserved between
different gp120s. The interface is centred on the residues
of the bridging sheet and the stem of the V1V2 loops [7];
this region is probably masked by the V2 and V3 loops in
the intact, non-CD4-induced gp120 molecule [16]. The
complementary determining regions (CDRs) of the 17b
light chain may make contact with the gp120 V3 loop in
the intact gp120 molecule.
Implications for gp120–receptor interactions
The interactions between gp120 and its receptors are
clearly complex and require a conformational change that
is induced by CD4 binding [8,9,15,17]. Although missing
in the structure, experimental evidence suggests convinc-
ingly that the V1 and V2 loops partially mask the CD4bs
[16]; this masking is more complete in clinically relevant
‘primary isolate’ viruses (as opposed to laboratory-adapted
viruses, reviewed in [18]), and is fully manifest only in the
oligomeric, functional form of gp120 [18]. Within an Env
oligomer, the CD4bs of gp120 probably fluctuates
between an ‘open’ and ‘closed’ conformation, and primary
isolates would have an equilibrium in favour of the closed
state. Multivalent attachment between a gp120 oligomer
and a cluster of CD4 molecules induces the conforma-
tional change required to expose the otherwise occluded
CRbs, and to ‘loosen’ the association with gp41 [19,20].
The V3 loop has been shown experimentally to become
more exposed after CD4 binding [5] and this probably
represents its movement away from the conserved
segment of the CRbs, allowing the efficient binding of
antibodies such as 17b. The CD4 molecule contains flexi-
ble segments [21] allowing gp120 to drop down onto the
chemokine receptor bringing the virus and cell mem-
branes into close proximity. The binding of gp120 to the
coreceptor may then induce further conformational
changes within the oligomer that activate the fusion
machinery of gp41, liberating the fusion peptide and
leading to virus–cell-membrane fusion.
Implications for viral evasion of neutralizing antibodies
In vivo, Env is subjected to intense pressure from the
immune response, particularly in the form of neutralizing
antibodies. The principal defence mechanisms adopted
by HIV involve extensive glycosylation and the use of
hypervariable loops, that can support significant structural
polymorphism, to occlude regions that are critical for viral
function. As part of this process of antibody evasion, the
CD4bs has developed several important characteristics.
Firstly, the CD4bs is partially masked by the hypervari-
able V1 and V2 loops and their associated glycosylation.
Secondly, the binding site is recessed to an extent that
would impede direct access of an antibody variable region,
and residues flanking the site are variable or shielded by
glycosylation. Thirdly, despite being relatively well con-
served, the CD4bs contains clusters of residues that do
not contact CD4 and are subject to mutation, such as
those lining the hydrophilic cavity. Finally, many gp120
residues contact CD4 via their mainchain atoms, allowing
for antibody recognition of the potentially variable side-
chains in the CD4 unbound state.
Potential for therapeutic and immunological intervention
One of the most impressive implications of the gp120
structure is the comprehensive manner in which the virus
has evolved to protect its most sensitive surfaces. As
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Figure 3
Ribbon diagram of the structure of the gp120 core. α Helices are
depicted in red, β strands in pink and the disordered V4 loop is
represented by a dashed line. Strand β15 of gp120 marked in yellow,
makes an antiparallel β-sheet alignment with the C′′ strand of CD4.
Marked are the inner and outer domains linked by the bridging sheet,
the base of the V1, V2 and V3 loops, the N and C termini and the virus
membrane proximal and distal faces. The gp41 molecule would be
membrane proximal, and would associate with the extended N and C
termini. The approximate location of the hydrophobic and hydrophilic
cavities are marked by a red and a blue star, respectively. (The figure
was reproduced from [13] with permission.)
mentioned above, the virus has adopted a range of
defence strategies including the occlusion of receptor-
binding sites with highly variable loops, glycosylation,
steric constraints and conformational shifts. This phenom-
enon explains to a great extent the poor immunogenicity
of the conserved portions of Env, shedding light on the
slow and generally weak neutralizing antibody response
characteristic of HIV infection [18]. Indeed, not only does
the virus use these mechanisms to avoid neutralization,
but goes two steps further. Firstly, the surfaces masked in
the trimeric form of gp120 (the ‘non-neutralizing’ face in
the structure; Figure 4b) and the N and C termini that
interact with gp41 become exposed in the monomeric,
soluble form of gp120. Spontaneous dissociation of gp120
from gp41, or release of gp120 or the precursor gp160 from
dying, infected cells therefore results in presentation to B
cells of highly antigenic segments of the molecule that are
irrelevant to neutralization [22]. Secondly, attachment of
the virus to CD4 exposes the CRbs, potentially exposing
this surface to antibody attack. In order to overcome this
vulnerability, CD4 binding orientates the CRbs towards
the cell membrane, which would present a steric barrier to
antibody binding [23].
The use of gp120 as a vaccine immunogen presents
significant difficulties, as witnessed by numerous failures 
to generate an effective neutralizing response against
primary isolates. A successful strategy may require solu-
tions at several levels, such as targeting constitutively
exposed, highly conserved regions of gp120 (such as the
b12 [24] and 2G12 [25] epitopes), isolating antibodies that
can induce conformational changes in primary isolate Env
[26], and altering Env immunogenicity by modifying the
gp120 structure [23] and glycosylation pattern [27].
Sensitive regions of gp120 protected from antibody
attack may be targets of therapeutic intervention. Several
possibilities might be envisaged. Firstly, it may prove
possible to develop molecules that target a region of
gp120 that induces conformational changes, resulting in
exposure of the CD4bs and/or the CRbs, or possibly
inducing gp120 dissociation from gp41 [19]. A second
possibility would involve a small molecule that binds to a
conserved portion of the CD4bs or CRbs that is not
masked by hypervariable loops, and prevents interaction
with these ligands. Thirdly, a bispecific molecule could
be designed to target two sites, one exposed and one pro-
tected (e.g. the CD4bs or CRbs and another conserved
region such as the 2G12 antibody epitope). Initial
binding to the exposed 2G12 epitope via the first ‘arm’
might then allow the second ‘arm’ to attach to the recep-
tor-binding site when it became exposed. A final possi-
bility might envisage a small molecule that could
potentially slip into the hydrophobic cavity formed after
CD4 binding and interfere with the further conforma-
tional changes necessary for fusion.
In conclusion, in one leap we have come a very long way
in our understanding of the structure and function of HIV
gp120. The information obtained is sobering; the virus has
evolved a tight system of self-defence against antibody
attack that defies easy solutions. We can now see our
adversary clearly, however, and can therefore begin to
devise immunological and therapeutic strategies aimed at
preventing the earliest steps in HIV infection.
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Figure 4
Functional and antigenic features of the
gp120 core. (a) The CD4- and conserved
coreceptor-binding surfaces. The gp120 core
structure is shown as in Figure 3, but tilted
slightly towards the membrane proximal face
(see arrow) so as to highlight the conserved
CRbs and V3 base. The CD4bs is shown in
red, the CRbs in green, and the V3 base in
purple. (b) Antigenic topography of the
gp120 core. The topography has been
defined by extensive monoclonal antibody
mapping using cross-competition analysis and
mutant binding studies. The relatively
restricted ‘neutralizing face’ is represented in
green, and comprises the CD4bs, regions of
the conserved CRbs and the V2 and V3 loops
(not present in the structure). The
‘immunosilent face’ in yellow is heavily
glycosylated and contains the variable loops
V4 (not present) and V5; only one known
neutralizing antibody epitope exists on this
face, that of the 2G12 antibody [25]. The
‘non-neutralizing face’ is shown in red, and is
obscured by complex formation with gp41
and interfacing with other gp120 molecules in
the oligomeric form of Env. (The figure was
reproduced from [23] with permission.)
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